
The study analyzed 569 metastatic prostate cancer (mPCa) patients treated with abiraterone. Of these, 40 (7.0%) had ductal features. The study found no significant differences in PSA response, PSA progression-free survival (PSA-PFS), or radiographic progression-free survival (rPFS) between patients with and without ductal features in both the metastatic hormone-sensitive (mHSPC, N=165) and castration-resistant prostate cancer (mCRPC, N=404) cohorts.
Like
Save
Share